Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sphingosine 1-phosphate
(
S1P
) plays important roles in cell proliferation, differentiation or survival mainly through its surface G-protein-coupled receptors S1P1-5. Bone represents the major site of metastasis for prostate cancer (CaP) cells, which rely on bone-derived factors to support their proliferation and resistance to therapeutics. In the present work we have found that conditioned medium (CM) from the MC3T3 osteoblastic cell line or primary murine and human osteoblast-like cells, as well as co-culture with MC3T3 stimulate proliferation of CaP lines in
S1P
-dependent manner. In addition, osteoblastic-derived
S1P
induces resistance of CaP cells to therapeutics including chemotherapy and radiotherapy. When
S1P
release from osteoblastic cells is decreased (inhibition of SphK1, knock-down of SphK1 or the
S1P
transporter, Spns2 by siRNA) or secreted
S1P
neutralized with anti-
S1P
antibody, the proliferative and survival effects of osteoblasts on CaP cells are abolished. Because of the paracrine nature of the signaling, we studied the role of the
S1P
receptors expressed on CaP cells in the communication with
S1P
secreted by osteoblasts. Strategies aimed at down-regulating S1P1, S1P2 or S1P3 (siRNA, antagonists), established the exclusive role of the
S1P
/S1P1 signaling between osteoblasts and CaP cells.
Bone metastases
from CaP are associated with osteoblastic differentiation resulting in abnormal bone formation. We show that the autocrine
S1P
/S1P3 signaling is central during differentiation to mature osteoblasts by regulating Runx2 level, a key transcription factor involved in osteoblastic maturation. Importantly, differentiated osteoblasts exhibited enhanced secretion of
S1P
and further stimulated CaP cell proliferation in a
S1P
-dependent manner. By establishing the dual role of osteoblast-borne
S1P
on both osteoblastic differentiation and CaP cell proliferation and survival, we uncover the importance of
S1P
in the bone metastatic microenvironment, which may open a novel area of study for the treatment of CaP bone metastasis by targeting
S1P
.
...
PMID:Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. 2476 38